Updating Authorized Representative Data in Russia: Two Deadlines to Track

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Government Resolution No. 1206, dated 13 August 2025 and in force from 5 November 2025, amends paras. 7 and 29 of Resolution No. 1684 and extends the deadline for updating the data of the authorized representative to 1 September 2026. The sanction in subpara. е of para. 137, under which the registration is suspended for 90 working days and then revoked if the deficiency is not cured, applies from 1 September 2027. The two dates belong to different tracks: one is the deadline for the update, the other is the starting point of enforcement. The year between them is the remediation window, and manufacturers who use it deliberately can complete their updates without pressure, while those who wait will face a compressed timeline shared with every other late mover in the market.

The distinction between the two dates is the single most important planning fact in this area. A company that treats 1 September 2026 as a soft target risks discovering, in the worst case, that an uncorrected file becomes subject to the suspension and revocation mechanism from 1 September 2027. A company that schedules the update in the first half of 2026 retains buffer time to fix data quality problems that inevitably surface during the review, such as outdated addresses, expired powers of attorney or signatories who have left the representative organization.

2. Legal basis

Three government resolutions together define the update obligation, its deadline and the validity of the underlying rules. The table below lists each instrument with its reference number, date and the provisions relevant to the update exercise.

Legal actReferenceDateProvisions
Government Resolution of the Russian Federation amending Resolution No. 1684Government Resolution No. 120613 August 2025 (in force from 5 November 2025)amends paras. 7 and 29; data update deadline 1 September 2026
Government Resolution of the Russian Federation on the National Rules for the State Registration of Medical DevicesGovernment Resolution No. 168430 November 2024paras. 7 and 29; subpara. е of para. 137 (sanctions from 1 September 2027)
Government Resolution of the Russian Federation extending the validity of the rulesGovernment Resolution No. 221430 December 2025the rules remain in force until 31 December 2028

3. Expert insights

Insight one: this is a compliance action for existing certificates, not a matter for new applications. Every foreign manufacturer holding registration certificates under the Resolution No. 1684 rules should verify whether the representative data in the dossier matches the current situation. That check covers the legal name and address of the representative, the validity of the power of attorney, and the authority of the actual signatory. Data that was accurate at the moment of registration may have drifted: representative companies reorganize, offices move, signatories change, and powers of attorney expire. The update exercise is the legislated opportunity to bring the register back in line with reality before enforcement begins.

Insight two: the sanction mechanism is two-staged, combining suspension and revocation. Subpara. е of para. 137 applies from 1 September 2027: first the registration is suspended for 90 working days, and if the deficiency is not cured within the suspension period the registration is revoked. The remediation clock runs in working days, not calendar days. For a manufacturer relying on Russian revenue, a 90-working-day suspension of the certificate is effectively a market exit for the affected devices, and a revocation would require starting the registration process again from the beginning. The asymmetry between the modest cost of a proactive update and the severity of the sanction makes the decision straightforward.

Insight three: the update is a natural occasion for a systematic cleanup. While the representative data is being verified, manufacturers should review consistency across the whole file: production addresses, model configurations, trademark ownership documents and QMS certificates. Bundling several changes into one coordinated submission reduces the number of separate filings, the number of fee payments and the administrative load on the representative. Companies that treat the deadline merely as a data patch miss the chance to clear the backlog of accumulated inconsistencies in a single pass.

Insight four: sequencing matters when multiple entities are involved. Where the representative has changed since the original registration, the update involves both the new appointment documents and the amendment of the register entry. Coordinating the notarization of new powers of attorney with the amendment filing is a project in itself, and starting early in the window is the only way to keep it clear of the 2027 enforcement date.

4. Practical recommendations

The steps below convert the two statutory dates into an actionable internal plan. They assume a portfolio of certificates held under the Resolution No. 1684 rules and a representative structure that may have drifted from the registered data.

  1. Set 1 September 2026 as an internal hard deadline and complete the verification and update of all representative data before that date, leaving the remainder of the window as buffer.
  2. Use a single reconciliation sheet to compare, item by item, the register record, the power of attorney, the service agreements and the actual signatory of the representative.
  3. Bundle other pending changes with the representative data update, so that filings are consolidated instead of being scattered across the period approaching 1 September 2027.
  4. Escalate internally any certificate whose update cannot be completed early, and assign an owner with a recovery plan for each such case.

5. Verification checklist

Confirm each item below for every certificate in the portfolio before treating the update exercise as closed. The checklist mirrors the data elements named in the amended provisions.

  • □ The name and address of the representative in the dossier match the actual situation
  • □ The power of attorney of the authorized representative is valid and has a notarized Russian translation
  • □ The update has been completed before 1 September 2026
  • □ A consistency recheck has been scheduled ahead of 1 September 2027
  • □ Changes relating to the representative have been bundled with other pending changes

Regulatory information verified as of 29 October 2026.

GRZAN supports medical device manufacturers with the representative data update in Russia: auditing register entries against current corporate documents, preparing amendment filings, renewing powers of attorney and building a consolidated schedule across the whole certificate portfolio before the statutory deadlines. For assistance with the update program, contact GRZAN at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail